Table 1 Main characteristics of all the studies included in the meta-analysis (no. = 3338)
Author | Year | Country | Ethnicity | No. (M/F) | Follow-up (months) (median and range) | Treatment | Age (years; mean ± SD) | Cut-off value | Outcome | Stage | Type | Variable type | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Manabu et al. [30] | 2019 | Japan | Asian | 67 (40/27) | NR | Mix | 68 (46–80) | 4 | OS | IIa–III | PC | UV | 6 |
Shinichi et al. [34] | 2019 | Japan | Asian | 136 (76/60) | 16.8 (1.3–104.3) | Surgery | 68 (33–86) | 4.6 | OS | I–IV | PDAC | UV | 5 |
Toshiya et al. (1) [29] | 2018 | Japan | Asian | 329 (131/198) | NR | Surgery | 67 (61–74) | 3 | OS/DFS | 0–III | PDAC | UV | 5 |
Toshiya et al. (2) [29] | 2018 | Japan | Asian | 95 (39/56) | NR | Surgery | 65 (58–69) | 3 | OS | – | PDAC | UV/MV | 5 |
Sierzega et al. [40] | 2017 | Poland | Caucasian | 442 (182/260) | 93 (15–290) | Surgery | 60 (55–66) | 3 | OS | IA–III | PDAC | UV/MV | 5 |
Singh et al. [27] | 2017 | USA | Mixed | 97 (97/0) | NR | Mixed | 66 ± 0.9 | 2.05 | OS | I–IV | PDAC | UV | 6 |
Xue et al. (1) [39] | 2017 | China | Asian | 153 (102/51) | 8.8 (0.5–75.5) | Chemotherapy | 60 (34–86) | 2.8 | OS | III–IV | PDAC | UV/MV | 6 |
Xue et al. (2) [39] | 2017 | Japan | Asian | 252 (133/119) | NR | Chemotherapy | 67 (31–86) | 2.8 | OS | III–IV | PDAC | UV/MV | 6 |
Yu et al. (1) [38] | 2017 | China | Asian | 139 (83/56) | 78 | Chemotherapy | < 60, 54 ≥ 60, 85 | 3.19 | OS | III–IV | PDAC | UV/MV | 5 |
Yu et al. (2) [38] | 2017 | China | Asian | 225 (146/79) | 78 | Chemotherapy | < 60, 78 ≥ 60, 147 | 3.19 | OS | III–IV | PDAC | UV/MV | 5 |
Li et al. [26] | 2016 | China | Asian | 144 (77/67) | 14 (6–40) | Surgery | 62 ± 2.8 | 2.86 | OS/RFS | I–III | PDAC | UV/MV | 6 |
Qi et al. (1) [31] | 2016 | China | Asian | 177 (108/69) | NR | Chemotherapy | 58.8 ± 10.7 | 3 | OS/TTP | III–IV | PDAC | UV/MV | 6 |
Qi et al. (2) [31] | 2016 | China | Asian | 321 (208/113) | NR | Chemotherapy | 61.0 ± 10.1 | 3 | OS/TTP | III–IV | PDAC | UV/MV | 6 |
Qi et al. (3) [31] | 2016 | China | Asian | 76 (46/30) | NR | Chemotherapy | 60.9 ± 9.6 | 3 | OS/TTP | III–IV | PDAC | UV/MV | 6 |
Qi et al. [37] | 2015 | China | Asian | 211 (134/77) | NR | Chemotherapy | 61.2 ± 10.7 | 3.33 | OS | III–IV | PDAC | UV/MV | 6 |
Stotz et al. [28] | 2015 | Austria | Caucasian | 474 (256/218) | 36 (0–162) | Mix | 64.6 ± 10.4 | 2.8 | OS | I–IV | PDAC | UV/MV | 6 |